The assay (primers and probes only) is designed for the detection of the ALK (Anaplastic Lymphoma Kinase) G1269A mutation in tissue DNA and cfDNA of plasma samples.
ALK was initially identified in a specific subtype of anaplastic large cell lymphoma (ALCL), which led to its designation as anaplastic lymphoma kinase (ALK). Subsequently, ALK gene rearrangements were discovered in non-small cell lung cancer, as well as in other conditions such as diffuse large B-cell lymphoma and inflammatory myofibroblastic tumor (IMT). These discoveries demonstrated the presence of various ALK gene rearrangements in different tumor types. ALK functions as a potent oncogenic driver gene, contributing to the development and progression of these malignancies.